Rucaparib Camsylate (Rubraca)



Rucaparib 283173-50-2
Rucaparib Camsylate 1859053-21-6

Rubraca® (rucaparib) tablets

CLOVIS ONCOLOGY

Fast facts about Rubraca:

- Accelerated approval by FDA on Dec. 19, 2016
- For treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies
- A Poly (ADP-ribose) polymerase (PARP) inhibitor used as an anti-cancer agent
- Drug targeting the DNA repair enzyme PARP-1
- Rucaparib is the second PARP inhibitor to be approved for BRCA-mutated ovarian cancer. The first, olaparib (Lynparza®), received approval in 2014 for ovarian tumors that have been treated with three or more chemotherapies.
- Sold by Clovis Oncology Inc.
- The recommended dose and schedule for rucaparib is 600 mg (two 300 mg tablets) taken orally twice daily with or without food.



Cells with treatment-induced DNA damage, marked by red staining. When a cell accumulates enough DNA damage, it dies. PARP inhibitors prevent cancer cells from repairing DNA damage.
Photo Credit: National Cancer Institute

Pharmacokinetic data	
Bioavailability	30–45% (T_{max} = 1.9 hours)
Protein binding	70% (*in vitro*)
Metabolism	Liver
Elimination half-life	17–19 hours

WO2006033003A1 (Decagram scale)



Rucaparib Camsylate (Rubraca)



Org. Process Res. Dev. 2012, *16*, 1897-1904. (Multikilogram scale)